Anti-SPPL2C monoclonal antibody

Pre-made anti-SPPL2C monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SPPL2C/SPPL2C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1813-Ab-1/ GM-Tg-hg-IP1813-Ab-2Anti-Human SPPL2C monoclonal antibodyHuman
GM-Tg-rg-IP1813-Ab-1/ GM-Tg-rg-IP1813-Ab-2Anti-Rat SPPL2C monoclonal antibodyRat
GM-Tg-mg-IP1813-Ab-1/ GM-Tg-mg-IP1813-Ab-2Anti-Mouse SPPL2C monoclonal antibodyMouse
GM-Tg-cynog-IP1813-Ab-1/ GM-Tg-cynog-IP1813-Ab-2Anti-Cynomolgus/ Rhesus macaque SPPL2C monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1813-Ab-1/ GM-Tg-felg-IP1813-Ab-2Anti-Feline SPPL2C monoclonal antibodyFeline
GM-Tg-cang-IP1813-Ab-1/ GM-Tg-cang-IP1813-Ab-2Anti-Canine SPPL2C monoclonal antibodyCanine
GM-Tg-bovg-IP1813-Ab-1/ GM-Tg-bovg-IP1813-Ab-2Anti-Bovine SPPL2C monoclonal antibodyBovine
GM-Tg-equg-IP1813-Ab-1/ GM-Tg-equg-IP1813-Ab-2Anti-Equine SPPL2C monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1813-Ab-1/ GM-Tg-hg-IP1813-Ab-2; GM-Tg-rg-IP1813-Ab-1/ GM-Tg-rg-IP1813-Ab-2;
GM-Tg-mg-IP1813-Ab-1/ GM-Tg-mg-IP1813-Ab-2; GM-Tg-cynog-IP1813-Ab-1/ GM-Tg-cynog-IP1813-Ab-2;
GM-Tg-felg-IP1813-Ab-1/ GM-Tg-felg-IP1813-Ab-2; GM-Tg-cang-IP1813-Ab-1/ GM-Tg-cang-IP1813-Ab-2;
GM-Tg-bovg-IP1813-Ab-1/ GM-Tg-bovg-IP1813-Ab-2; GM-Tg-equg-IP1813-Ab-1/ GM-Tg-equg-IP1813-Ab-2
Products NameAnti-SPPL2C monoclonal antibody
Formatmab
Target NameSPPL2C
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SPPL2C monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1813-Ag-1Recombinant multi-species SPP2C/ SPPL2C/ IMP5 protein


    Target information

    Target IDGM-IP1813
    Target NameSPPL2C
    Gene ID162540,237958,287753,717107,490923,101081094,513917,100146935
    Gene Symbol and Synonyms4933407P14Rik,IMP5,RGD1560562,SPPL2C
    Uniprot AccessionQ8IUH8
    Uniprot Entry NameSPP2C_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000185294
    Target ClassificationN/A

    The target: SPPL2C, gene name: SPPL2C, also named as IMP5. Enables protein homodimerization activity. Predicted to be involved in membrane protein proteolysis. Located in endoplasmic reticulum membrane. Is integral component of cytoplasmic side of endoplasmic reticulum membrane and integral component of lumenal side of endoplasmic reticulum membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.